Impact News +++ CoreWeave vs. Nebius: Which AI Infrastructure Stock Is the Better Buy? (Fool) +++ NEBIUS Aktie -3,03%

GSK Aktie

>GSK Aktienkurs

21.4 EUR -2.5% (TradegateBSX)

Ask: 21.41 EUR / 1200 Stück

Bid: 21.41 EUR / 239 Stück

Tagesumsatz: 6055 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

GSK Aktie über LYNX handeln

Intraday

1 Jahr

>GSK Performance

1 Woche: +1,2%

1 Monat: -2,5%

3 Monate: +2,0%

6 Monate: -10,3%

1 Jahr: +28,9%

laufendes Jahr: +3,7%

>GSK Aktie

Profil:

GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, England. The company focuses on discovering, developing, and manufacturing prescription medicines and vaccines for a wide range of diseases. GSK plc ..
>Volltext..

Insiderhandel:

>GSK Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>GSK Anleihen

>GSK Peer Group

Gesundheit, AIDS/ HIV- Behandlung, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika, mRNA- & RNA- Therapien/ Forschung, Lungen- & Atemwegserkrankungen/ -behandlung
>Alle Branchen..

>GSK Chart & Kurs - Tradegate
- Boerse Frankfurt
- Boerse Stuttgart
- Gettex
- OTC
- Tradegate
- Xetra
- >Profi Charts

>GSK News

04.09.26 - 13:42	Health Care Roundup: Market Talk (WSJ EN)
	Find insight on GSK, AstraZeneca, Bayer and more in the latest Market Talks covering health care....

04.09.26 - 12:24	GSK′s mRNA flu vaccine data closely tracks Moderna′s, Deutsche Bank says (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

04.09.26 - 05:45	Research: CLSA Maintains HUTCHMED at Outperform, Says ATTC Platform Gains Recognition From Multinational Pharma Firm (AAStocks)
	CLSA issued a research report on HUTCHMED (00013.HK), which licensed the ex-China rights of its KRAS-EGFR ATTC candidate HMPL-A830 to GSK, receiving an upfront payment of USD110 million and milestone payments of up to USD1.3 billion. The broker viewed the transaction represents strong recognition of the company's ATTC platfo......

04.09.26 - 05:30	Research: Citi Lifts HUTCHMED TP to HKD39, Reiterates Buy/High Risk Rating (AAStocks)
	HUTCHMED (00013.HK) and GSK sealed a licensing deal for HMPL-A830 (KRAS-EGFR ATTC). In a research report, Citi said GSK's endorsement validated the ATTC platform concept, and the deal was reached earlier than the broker had expected.Citi expected first patient dosing for HMPL-A251 and HMPL-A580 from end-2026 to early 2027, w......

03.09.26 - 19:45	Does Moderna′s mRNA Flu Shot Face a New Challenge From GSK? (Zacks)
	MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins....

03.09.26 - 16:33	Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth \| DelveInsight (PR Newswire)
	The osteosarcoma treatment pipeline is gradually expanding, with emerging therapies such as OST-HER2 (OS Therapies), DANYELZA (naxitamab-gqgk; SERB Pharmaceutical), Vactosertib (MedPacto), Risvutatug rezetecan (GSK), Olaparib with Ceralaserti (AstraZeneca), OMO-103 (Peptomyc),......

03.09.26 - 16:30	Milliarden-Deal mit GSK beflügelt HUTCHMED Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.09.26 - 12:24	Panmure and Cavendish reiterate buy on Hutchmed after GSK deal (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

03.09.26 - 12:12	Hutchmed China inks USD1.30 billion GSK deal for cancer drug HMPL-A830 (Alliance)
	Hutchmed China PLC on Thursday announced that its subsidiary, Hutchmed Ltd, has entered into an exclusive development licence...

03.09.26 - 10:57	HUTCHMED jumps 15% after licensing cancer therapy to GSK for up to $1.295B (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.09.26 - 09:36	HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

03.09.26 - 07:30	HUTCHMED Leaps 11%+ on Heavy Vol. after Reaching Licensing Deal With GSK for KRAS-EGFR Antibody-drug Conjugate Cancer Therapy (AAStocks)
	HUTCHMED (00013.HK) surged in the afternoon session today (3rd) after reaching a licensing agreement with GSK for a KRAS-EGFR antibody-drug conjugate cancer therapy. The stock once peaked at HKD22.3. It last printed at HKD21.36, up 11.6%, with volume surging to 11.6735 million shares, involving HKD250 million.HUTCHMED announced ......

03.09.26 - 06:45	HUTCHMED Reaches Licensing Agreement With GSK for KRAS-EGFR Antibody-Drug Conjugate Cancer Therapy (AAStocks)
	HUTCHMED (00013.HK) announced that it has entered into an exclusive development and license agreement with a subsidiary of GSK plc, granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. Clinical development will initially focus on colorectal, pa......

02.09.26 - 13:06	GSK Hold (DPA-AFX)
	FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für GSK mit einem Kursziel von 2000 Pence auf "Hold" belassen. Dies schrieb Emmanuel Papadakis in seinem am Mittwoch vorliegenden Kommentar zu den wöchentlichen Verschreibungszahlen./ag/bekVeröffentlichung ......

01.09.26 - 20:00	Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III (24/7 Wall St.)
	Today's major mRNA headline is a competitive threat to Moderna (NASDAQ:MRNA), and the stock is climbing anyway. That tension is the story on the tape, and it's worth reading as a platform bet rather than a flu vaccine call. This MRNA stock rally sits inside a much larger year-to-date advance, so the reaction function matters […]...

01.09.26 - 17:30	GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? (Zacks)
	GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains....

01.09.26 - 15:06	4 stocks to watch on Tuesday: GSK, GPRO, DUOL, and MU (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.09.26 - 12:48	GSK advances mRNA flu shot after Phase II success (ShareCast)
	Drugmaker GSK said on Tuesday that it will move its mRNA seasonal flu vaccine candidate into Phase III after reporting positive Phase II results at the OPTIONS XIII influenza conference....

01.09.26 - 12:30	GSK Underweight (DPA-AFX)
	NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK mit einem Kursziel von 1700 Pence auf "Underweight" belassen. Aktuellen Branchendaten des Auftragsforschers Iqvia zufolge habe sich das Wachstum des Krebsmedikaments Jemperli ......

01.09.26 - 10:12	GSK überführt mRNA-Grippeimpfstoff in die nächste Studienphase (Dow Jones)
	Von Adria Calatayud DOW JONES--GSK kommt mit der Entwicklung eines auf mRNA basierenden Grippeimpfstoffs voran. Wie der britische Pharmakonzern mitteilte, beginnt für den Impfstoffkandidaten noch im September eine Spätphasenstudie. ......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wenn wir nur das Unrecht hassen und nicht diejenigen, die es tun, werden wir unsere Kampfgenossen und unsere Feinde lieben. - Freifrau Marie von Ebner-Eschenbach

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram